working

Sign in

This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account

This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account


Sign In
Not a commercial user? Register here for our wider research bundle

More Content

More Content

H1 surpassed expectations, Bimzelx’s US approval much-awaited in Q3

Companies: UCB (UCB:EBR)UCB S.A. (UCB:BRU)

Strong start to the year

Companies: UCB S.A.

Hardman & Co Monthly: April 2023

Companies: PIN APAX 4503 BHC 4568 FCSS GLXO HLUNB HIK HZNP IBT JAZZ JAZZ JNJ JNJ 4578 REGN REGN STX 4507 4506 4502 TEVA UTHR UTHR VRTX VRTX VTRS UCB UCB SAN SAN PFE PFE PFIZ NOVOB NOVOB NOT MRNA MRNA MRK ME*

Solid FY 16 guidance amid uncertainty on Romosozumab

Companies: UCB S.A.

Exceeded 2022 expectations; promising prospects, despite muted 2023 guidance

Companies: UCB (UCB:EBR)UCB S.A. (UCB:BRU)

© Research Tree 2025

  • Apple Store
  • Play Store

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top